highly significantp<0.001
In contrast, CMC2.24 treatment produced a highly significant (p<0.001) 27% reduction in alveolar bone loss ( Figure 5A and B ).
In contrast, CMC2.24 treatment produced a highly significant (p<0.001) 27% reduction in alveolar bone loss ( Figure 5A and B ).
36 CMC2.24 treatment significantly reduced TLR-2 (p<0.05) by 50.9%, (TLR-4 also showed a trend of reduction, but this effect was not statistically significant; data not shown) and also decreased p38 MAPK (p<0.05) by 37.2%, at the 3-month time period, compared to placebo.